Zobrazeno 1 - 10
of 400
pro vyhledávání: '"Mark C, Genovese"'
Autor:
Robin K. Dore, Jenya N. Antonova, Chakkarin Burudpakdee, Lawrence Chang, Magdaliz Gorritz, Mark C. Genovese
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 6, Pp 473-482 (2022)
Objective Comorbidities in rheumatoid arthritis (RA) can influence treatment selection, impact treatment persistency, and increase health care costs. This study assessed the magnitude of comorbidity burden via epidemiology (incidence and prevalence)
Externí odkaz:
https://doaj.org/article/c0dfab1d34814e2183ef6baf5642161b
Autor:
Mark C. Genovese, Patrick Durez, Roy Fleischmann, Yoshiya Tanaka, Daniel Furst, Hisashi Yamanaka, Elena Korneva, Igor Vasyutin, Tsutomu Takeuchi
Publikováno v:
European Journal of Rheumatology, Vol 8, Iss 3, Pp 120-129 (2021)
Externí odkaz:
https://doaj.org/article/f333c31940844bd68abc7f0c2b9f4be7
Autor:
Mark C. Genovese, Gerd R. Burmester, Owen Hagino, Karthinathan Thangavelu, Melitza Iglesias-Rodriguez, Gregory St John, Miguel A. González-Gay, Thomas Mandrup-Poulsen, Roy Fleischmann
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-12 (2020)
Abstract Background Diabetes is common in patients with rheumatoid arthritis (RA). Interleukin (IL)-6 is implicated in both the pathogenesis of RA and in glucose homeostasis; this post hoc analysis investigated the effects of IL-6 receptor vs. tumour
Externí odkaz:
https://doaj.org/article/3a969e68370045a191ca64cd450c21ad
Autor:
Josef S. Smolen, Young Mo Kang, Wan-Hee Yoo, Paul Emery, Michael E. Weinblatt, Edward C. Keystone, Mark C. Genovese, Gihyun Myung, Inyoung Baek, Jeehoon Ghil
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-9 (2020)
Abstract Objective Phase III clinical trials of the tumour necrosis factor inhibitors SB4, SB2, and SB5 (biosimilars to etanercept, infliximab, and adalimumab, respectively) have demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA).
Externí odkaz:
https://doaj.org/article/078e3fc0c86e4ce59dfa6b3cf0caed92
Autor:
Mark C. Genovese, Roy Fleischmann, Alan Kivitz, Eun-Bong Lee, Hubert van Hoogstraten, Toshio Kimura, Gregory St John, Erin K. Mangan, Gerd R. Burmester
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-17 (2020)
Abstract Background The interleukin-6 receptor inhibitor sarilumab demonstrated efficacy in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or as monotherapy in patients with moderately to severely active rheu
Externí odkaz:
https://doaj.org/article/12ab6b3c9513426f81af28505c83a39c
Autor:
Mark C. Genovese, Juan Sanchez-Burson, MyungShin Oh, Eva Balazs, Jeffrey Neal, Andrea Everding, Tomas Hala, Rafal Wojciechowski, Gary Fanjiang, Stanley Cohen
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Abstract Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated. Here we report results from a comparative cl
Externí odkaz:
https://doaj.org/article/e2a683879e044250a24f928f8a9a03d4
Autor:
Bernard Combe, Proton Rahman, Hideto Kameda, Juan D. Cañete, Gaia Gallo, Noah Agada, Wen Xu, Mark C. Genovese
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-9 (2020)
Abstract Background The long-term safety was assessed in patients with psoriatic arthritis who were treated with ixekizumab in three clinical trials (SPIRIT-P1/-P2/-P3). Methods Integrated safety data from three trials (controlled and uncontrolled),
Externí odkaz:
https://doaj.org/article/644134f123754d11b972170b9cc0bab2
Autor:
Mark C. Genovese, Josephine Glover, Maria Greenwald, Wieslawa Porawska, Elias Chalouhi El Khouri, Eva Dokoupilova, Juan Ignacio Vargas, Mykola Stanislavchuk, Herbert Kellner, Elena Baranova, Nobuhito Matsunaga, Rieke Alten
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-12 (2019)
Abstract Objective To compare the efficacy, serum drug concentrations, immunogenicity, and safety of FKB327 with the adalimumab reference product (RP) in combination with methotrexate in patients with moderate-to-severe, active rheumatoid arthritis (
Externí odkaz:
https://doaj.org/article/1252aed2b70243f88faf1f3693138e6a
Autor:
Christine Radawski, Mark C. Genovese, Brett Hauber, W. Benjamin Nowell, Kelly Hollis, Carol L. Gaich, Amy M. DeLozier, Kelly Gavigan, Maria Reynolds, Anabela Cardoso, Jeffrey R. Curtis
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 3, Pp 461-471 (2019)
Abstract Introduction Many rheumatoid arthritis (RA) patients do not achieve their treatment goals and experience symptoms that affect psychosocial outcomes and daily activities. This study aimed to identify and quantify the unmet needs perceived by
Externí odkaz:
https://doaj.org/article/fa901e0bcc604700b2aab1e66f3a9da3
Autor:
Mark C. Genovese, Maria W. Greenwald, Sergio R. Gutierrez-Ureña, Mario H. Cardiel, Jeffrey E. Poiley, Anna Zubrzycka-Sienkiewicz, Christine E. Codding, Annie Wang, Weizhong He, Rebecca Amos, Raul Vinueza, Xuegong Wang, Jay P. Garg, Alan J. Kivitz
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 4, Pp 503-520 (2019)
Abstract Introduction Peficitinib is a novel orally bioavailable, once-daily Janus kinase (JAK) inhibitor approved in Japan for the treatment of rheumatoid arthritis (RA). This 2-year extension study of two global phase IIb trials investigated the lo
Externí odkaz:
https://doaj.org/article/b2f958b58ad64477b1ce0db746636e51